GEN Exclusives

More »

GEN News Highlights

More »
Sep 15, 2009

Revotar Wins Roughly $3.65M to Progress Selectin Antagonists Against Respiratory Conditions

  • Revotar Biopharmaceuticals received a €2.5 million (about $3.65 million) grant from the German Federal State of Brandenburg to support development of its selectin antagonist pipeline in respiratory indications.

    The company’s lead pan-selectin inhibitor candidate, bimosiamose, has already undergone Phase IIa trials in asthma, COPD, and psoriasis. An additional Phase IIa trial in COPD is due to start in 2010.

    Selectins are a family of three, structurally similar carbohydrate-binding cell-adhesion molecules (E-, P-, L-selectin), which play a key inflammatory role by increasing the adhesion of different leukocytes from the bloodstream to the surface of the blood vessels surrounding the area of inflammation. Revotar claims Bimosiamose is capable of antagonizing all three selectins, so blocking extravasation of leukocytes from the circulation into inflamed surrounding tissue.

     



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?